Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

被引：0
|
作者：
W Chua
D Goldstein
C K Lee
H Dhillon
M Michael
P Mitchell
S J Clarke
B Iacopetta
机构：
[1] Sydney Cancer Centre,Department of Medical Oncology
[2] Concord Repatriation General Hospital,Department of Medical Oncology
[3] Prince of Wales Hospital,Division of Haematology and Medical Oncology
[4] NHMRC Clinical Trials Centre,Department of Medical Oncology
[5] Centre of Medical Psychology and Evidence-based Decision-Making,undefined
[6] University of Sydney,undefined
[7] Peter MacCallum Cancer Centre,undefined
[8] Austin Hospital,undefined
[9] School of Surgery,undefined
[10] University of Western Australia,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
colorectal cancer; metastatic; chemotherapy; predictive factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：998 / 1004
页数：6
相关论文
共 50 条
  • [21] FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer
    Kitayama, Joji
    Nozawa, Hiroaki
    Watanabe, Toshiaki
    Sunami, Eiji
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer
    Petrioli, Roberto
    Paolelli, Loretta
    Marsili, Stefania
    Civitelli, Serenella
    Francini, Edoardo
    Cioppa, Tommaso
    Roviello, Franco
    Nettuno, Raffaele
    Intrivici, Chiara
    Tanzini, Gabriello
    Lorenzi, Marco
    Francini, Guido
    ONCOLOGY, 2006, 70 (05) : 345 - 350
  • [23] Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer
    Ruan, Wen-Cong
    Che, Yue-Ping
    Ding, Li
    Li, Hai-Feng
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2018, 21 (10) : 718 - 724
  • [24] Possible molecular markers for efficacy of cetuximab in metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2005, 2 (8): : 381 - 381
  • [25] Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer
    Ronnekleiv-Kelly, Sean M.
    Burkhart, Richard A.
    Pawlik, Timothy M.
    SURGICAL ONCOLOGY-OXFORD, 2016, 25 (03): : 190 - 199
  • [26] Markers of metastatic colorectal cancer
    Mysliwiec, Piotr
    Choromanska, Barbara
    Dadan, Jacek
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2020, 15 (02): : 94 - 97
  • [27] SPRY2 and response to FOLFOX/CAPOX in metastatic KRAS mutated colorectal cancer
    Montal, R.
    Merche, M. -V.
    Anta, B.
    Martinez, N.
    Santos, C.
    Sanjuan, X.
    Paules, M. J.
    Perez Martin, F. J.
    Azuara, D.
    Salazar, R.
    Rojas, J. M.
    ANNALS OF ONCOLOGY, 2015, 26
  • [28] Response to FOLFOX chemotherapy in patients with colorectal cancer according to RRM2 expression
    Yan, Chongxian
    Fang, Zejun
    Liu, Hong
    Shao, Jianli
    Wang, Anhua
    Sun, Long
    Zhu, Zhihua
    Luo, Shuchai
    Chen, Xiang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (11): : 21970 - 21978
  • [29] Chemotherapy of metastatic colorectal cancer
    deGramont, A
    Louvet, C
    Andre, T
    Tournigand, C
    Raymond, E
    Krulik, M
    PRESSE MEDICALE, 1996, 25 (35): : 1678 - 1682
  • [30] BRCA mutations in metastatic colorectal cancer (mCRC) and response to chemotherapy
    Feng, Sophie
    Al-Showbaki, Laith
    Krzyzanowska, Monika K.
    Prince, Rebecca M.
    Stockley, Tracy
    Yu, Celeste
    Bedard, Philippe L.
    Siu, Lillian L.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345